Al though cardiovascular disease remains the leading cause of death worldwide, there has been tremendous success in its treatment over the last few decades, leading to a dramatic decline in age-adjusted cardiovascular mortality (1). This success is strongly attributed to effective management of acute, deadly manifestations such as myocardial infarction (2). Although more patients survive, they enter a subsequent stage of chronic disease with an injured heart. The prevalence of chronic heart failure is rising accordingly, posing a major challenge to the cardiovascular care of the future (3).This evolution of cardiovascular disease epidemiology is paralleled by an evolution of cardiovascular therapy. The currently available powerful armamentarium of interventional and surgical procedures, implantable devices, and antithrombotic and heart disease risk factor-modifying drugs is continuously expanded by the development and introduction of novel treatments with an ever-increasing specificity that seeks to modify selective molecular pathways or even entire systems of molecular and cellular interaction (2,4,5). The goal of such novel therapies is to enhance myocardial repair or even provide a causative modification of cardiac disease, so that-beyond the effective treatment of acute events-the development of a chronic disease state can be prevented or reversed. Similar to other fields of molecular medicine, such targeted therapies, based on, for example, antibodies, nanoparticles, RNAs, or engineered cells, will be expensive, and because of their specific nature, they are not expected to work in everybody. This emphasizes the need for effective biomarkers to implement a personalized approach toward therapy guidance. Accordingly, the quest for biomarkers in personalized medicine presents an opportunity for noninvasive imaging (4,6).The increasing range and increasing specificity of therapeutic options in cardiology are paralleled by an increasing range and increasing specificity of diagnostic imaging options, adding another layer to the evolution of cardiovascular medicine (Fig. 1). To meet